Home/Filings/4/0001439222-25-000002
4//SEC Filing

Milanova Tsveta 4

Accession 0001439222-25-000002

CIK 0001439222other

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 5:05 PM ET

Size

8.9 KB

Accession

0001439222-25-000002

Insider Transaction Report

Form 4
Period: 2025-01-03
Milanova Tsveta
Chief Commercial Officer
Transactions
  • Sale

    Common stock

    2025-01-06$32.18/sh2,804$90,23318,906 total
  • Exercise/Conversion

    Restricted stock units

    2025-01-038,4768,475 total
    Common stock (8,476 underlying)
  • Exercise/Conversion

    Common stock

    2025-01-03+8,47621,710 total
Footnotes (3)
  • [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated January 3, 2023.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F3]The restricted stock units were granted on January 3, 2023. Beginning on January 3, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001957180

Filing Metadata

Form type
4
Filed
Jan 6, 7:00 PM ET
Accepted
Jan 7, 5:05 PM ET
Size
8.9 KB